Adalimumab biosimilar - Prestige BioPharma
Alternative Names: Humira Biosimilar - Prestige Biopharma; PBP 1502Latest Information Update: 28 Mar 2025
At a glance
- Originator Prestige BioPharma
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Arthritis
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Arthritis(In volunteers) in Spain (SC, Injection)
- 30 Mar 2022 Phase-I clinical trials in Arthritis in Spain (SC) (NCT05108259)
- 23 Dec 2020 Phase-II clinical trials in Arthritis in Singapore (SC) (Prestige BioPharma pipeline, December 2020)